Prime Minister’s recent call-to-action to implement widespread cancer ‘one stop shops’ across the UK. In his 5 November announcement, Rt Hon Matt Hancock MP, the recently appointed Secretary of State for Health, stated his goal is to increase UK life expectancy by five years or more by 2035, re-emphasising the impact of preventative health strategies such as increased physical activity and smoking cessation. Without a re-think of population-scale, prevention strategies, I fear we will fall short of this ambition.
However, help is at hand. Whilst the stated goal of ‘diagnosing 75% of cancers at stages one and two by 2028’ is certainly ambitious, the good news is that we already have the technology to make it possible, starting with lung cancer.
Oncimmune Holdings plc (LON:ONC) operates as a cancer detection company. The Company focuses on the development of autoantibody assay technologies that allow cancer detection earlier than other methods and be applied to a wide range of solid tumour types.
